The diabetes drug Actos was recalled in France and Germany in June 2011 because studies showed it increased patients’ risks of developing bladder cancer and congestive heart failure. But instead of requesting an Actos recall n the U.S., the FDA merely issued a warning about the risk of bladder cancer.
In the time since France and Germany recalled Actos, there have been two new studies confirming the bladder cancer risk (June 1, 2012 and July 3, 2012). There has also been a study (June 11, 2012) showing that Actos increases the risk of macular edema, which causes blurred vision.
Actos bladder cancer victims have filed so many lawsuits that the federal lawsuits have been consolidated in Actos Multidistrict litigation. Both California and Illinois have a number of consolidated Actos lawsuits filed in their state courts.
According to an Associated Press article, Takeda Pharmaceutical Co., Ltd. (“Takeda”), the maker of Actos, took in $3.4 billion in sales of Actos in the U.S. in 2011. Pardon me if I wonder if the maker of Acts cares more about profits that it does the health of people with diabetes.
To try to build public support for an Actos recall, I’ve created a Recall Actos Facebook Page, a Recall Actos Google+ Page, a RecallActos Twitter account, and a RecallActos.com website where people can sign a petition calling for a recall.
The Actos lawsuit website includes shocking excerpts from an Actos whistleblower lawsuit filed by a former medical researcher for Takeda. The website also offers people with bladder cancer (and their family members) the opportunity to obtain a free Actos lawsuit review by calling 800-671-0996 toll free, 24 hours a day, 7 days a week or using the website’s Free Actos Lawsuit Review Form.
If you take Actos, you should continue taking it until you can schedule an appointment to discuss the drug’s risks with your doctor. And between now and your appointment, do some research on the risks of the drug. A good place to begin your research is the Actos Lawsuit Background post at Actos-Lawsuit.pro. That post gives a good history of the regulatory background and the studies regarding Actos and bladder cancer.
Actos® is one of the trade names under which the drug pioglitazone is marketed. ACTOS, ACTOplus met, ACTOplus met XR, and Duetact are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals U.S.A., Inc.